Vogt-Koyanagi-Harada Disease: A Case Series in a Tertiary Eye Center
Table 2
Clinical characteristics and management of the cases of VKH.
Case no.
Sex
Age (years)
Stage of presentation
Extraocular manifestation
Presenting VA
Final VA
Medical treatment
Surgical treatment
1
F
54
Acute uveitis
None
HM and HM
6/12 and 6/18
IV steroid, azathioprine
Cataract surgery
2
F
47
Acute uveitis
None
3/60 and 6/18
6/18 and 6/12
Oral steroid, methotrexate
Cataract surgery
3
M
30
Acute uveitis
None
HM and 1/60
6/6 and 6/9
IV steroid, azathioprine, ATT
4
F
49
Acute uveitis
Integumentary
6/12 and 6/24
6/12 and 6/24
Oral steroid
5
F
51
Chronic recurrent
None
6/9 and 6/12
6/18 and 6/18
Oral steroid, methotrexate, ATT
6
F
45
Convalescent
Neurological, integumentary, and auditory
6/18 and 6/9
6/9 and 6/6
Oral steroid, methotrexate
Cataract surgery, glaucoma filtration surgery
M: male; F: female; IV: intravenous; ATT: antitubercular treatment; HM: hand movement. Intravenous corticosteroid as a 500 mg injection of methylprednisolone, twice a day for 3 days. Oral corticosteroid as prednisolone tablet at a dose of 1 mg/kg. Azathioprine tablet at a dose of 1.5 mg/kg/day. Methotrexate tablet at a dose of 7.5 mg once a week along with 5 days of supplementary folic acid 5 mg a week after initial liver function testing.
